LivaNova LIVN Cardiopulmonary — Foreign currency translation adjustment
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by LivaNova in its filing.
Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.
The official record: LivaNova’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →
Ask your AI about LivaNova's cardiopulmonary — foreign currency translation adjustment.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is LivaNova's cardiopulmonary — foreign currency translation adjustment?
- LivaNova (LIVN) reported cardiopulmonary — foreign currency translation adjustment of $10.71M in Q4 2025.
- How has LivaNova's cardiopulmonary — foreign currency translation adjustment changed year-over-year?
- LivaNova's cardiopulmonary — foreign currency translation adjustment increased by 230.1% year-over-year, from -$8.23M to $10.71M.
- What is the long-term trend for LivaNova's cardiopulmonary — foreign currency translation adjustment?
- Over 4 years (2021 to 2025), LivaNova's cardiopulmonary — foreign currency translation adjustment has grown at a 17.1% compound annual growth rate (CAGR), from -$22.79M to $42.83M.
- What does cardiopulmonary — foreign currency translation adjustment mean?
- Reflects the impact of exchange rate fluctuations on the financial results of the Cardiopulmonary segment's international operations when translated into the reporting currency. This metric highlights the segment's exposure to global currency volatility and its effect on reported performance.